19 / 28
18/05/2018:
Patients in the monotherapy arms of
KN361 and IMVIGOR130 trials with
PD-L1 low status
have decreased survival
compared to patients who received
cisplatin- or carboplatin-based chemotherapy
EMA label
for first line in Cisplatin unfit patients
changed
:
* Pembrolizumab CPS ≥10
* Atezolizumab ≥5%
08/06/2018:
https://www.fda.gov/Drugs/DrugSafety/ucm608075.html https://www.ema.europa.eu/en/news/ema-restricts-use-keytruda-tecentriq-bladder-cancer